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Introduction: Mycobacterium tuberculosis (Mtb) is
transmitted from person to person via airborne droplet
nuclei. At the community level, Mtb transmission
depends on the exposure venue, infectiousness of the
tuberculosis (TB) index case and the susceptibility of
the index case’s social network. People living with HIV
infection are at high risk of TB, yet the factors
associated with TB transmission within communities
with high rates of TB and HIV are largely
undocumented. The primary aim of the Kopanyo study
is to better understand the demographic, clinical, social
and geospatial factors associated with TB and
multidrug-resistant TB transmission in 2 communities
in Botswana, a country where 60% of all patients with
TB are also infected with HIV. This manuscript
describes the methods used in the Kopanyo study.
Methods and analysis: The study will be conducted
in greater Gaborone, which has high rates of HIV and a
mobile population; and in Ghanzi, a rural community
with lower prevalence of HIV infection and home to the
native San population. Kopanyo aims to enrol all
persons diagnosed with TB during a 4-year study
period. From each participant, sputum will be cultured,
and for all Mtb isolates, molecular genotyping
(24-locus mycobacterial interspersed repetitive units-
variable number of tandem repeats) will be performed.
Patients with matching genotype results will be
considered members of a genotype cluster, a proxy for
recent transmission. Demographic, behavioural, clinical
and social information will be collected by interview.
Participant residence, work place, healthcare facilities
visited and social gathering venues will be geocoded.
We will assess relationships between these factors and
cluster involvement to better plan interventions for
reducing TB transmission.
Ethics: Ethical approval from the Independent Review
Boards at the University of Pennsylvania, US Centers
for Disease Control and Prevention, Botswana Ministry
of Health and University of Botswana has been
obtained.
INTRODUCTION
Tuberculosis (TB) continues to be a major
contributor to morbidity and mortality glo-
bally, particularly among persons infected
with HIV.1–3 TB in low-resource countries
accounts for the majority of the world’s
burden of the disease and increased global
migration threatens TB control efforts in low-
burden, high-resource countries.3 4 The
emergence of community-acquired
multidrug-resistant TB (MDR-TB) strains
emphasises the critical need for improving
TB control and prevention strategies.5–9
The WHO estimates that Botswana has one
of the highest TB notification rates in the
world.10 The high rate of TB is closely linked
to the high HIV seroprevalence in Botswana,
where ∼61% of patients with TB are also
infected with HIV (hereafter referred to as
TB/HIV).11 TB remains the leading cause of
death among people living with HIV/AIDS
in Botswana and worldwide.
Strengths and limitations of this study
Over the past two decades, the use of molecular
methods coupled with classical epidemiological
approaches has allowed researchers to detect previ-
ously undocumented tuberculosis (TB) transmis-
sion events and direct evidence for exogenous
reinfection among people with recurrent disease.
However, biased and underpowered study designs,
as well as the use of lower resolution genotyping
techniques, have limited our interpretation of these
studies. To our knowledge, the Kopanyo study will
be one of the largest prospective population-based
molecular epidemiological studies to assess factors
associated with TB transmission within entire com-
munities with high rates of HIV and TB.
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The design of effective TB prevention strategies
depends on our understanding of TB transmission in
communities. However, most interventions to prevent
ongoing TB transmission are based on data from the
pre-HIV and pre-MDR era, or from areas with low TB and
HIV prevalence. It is known that extensive and prolonged
exposure to someone with infectious TB disease increases
the risk of TB transmission,12 13 but little is known about
the role of casual or brief encounters, particularly among
persons with HIV-related immunosuppression.
Genotyping Mycobacterium Tuberculosis (Mtb) isolates
enables the visualisation of select genetic loci.14 Isolates that
share common genetic loci are referred to as genotypically
clustered, a potential marker for recent TB transmis-
sion.14 15 TB genotype clustering, when combined with epi-
demiological links between patients with TB, has improved
our understanding of TB transmission.14 15 However, many
TB molecular epidemiological studies have been limited by
some of the following methodological issues:
1. Limited enrolment of people with TB in a given com-
munity. Most molecular studies, particularly in high
TB incidence settings, have been based on conveni-
ence samples drawn from available clinical isolates of
Mtb.16–18 Moreover, passive (self-referral) TB index
case identification, or the omission of cases, has the
potential to introduce bias into a study,16 19 because
failure to include all cases into a TB genotyping
study can lead to unsolvable or biased investigations
of transmission chains because a given cluster with
missing cases cannot be fully reconstructed.
2. Limited temporospatial data for determination of
potential sites of transmission.
3. Limited molecular epidemiological analyses from set-
tings with high HIV prevalence. Therefore, the effect
of this key clinical and epidemiological factor on TB
transmission dynamics is not known.
4. Limited information regarding contacts and secondary
cases exposed to index cases. Retrospective clinical data
used in many studies do not include a comprehensive
list of people exposed to index cases and physical loca-
tions potentially involved in a transmission event.
STUDY GOALS
Kopanyo is the Setswana word meaning ‘to link’. Using
TB genotyping, geospatial analysis and patient inter-
views, we plan to link patients together to better under-
stand TB transmission networks and locations of
transmission. Our overarching goal is to better under-
stand transmission dynamics of TB within a country
characterised by high rates of TB and HIV, while addres-
sing what we perceive to be the major methodological
limitations of prior studies.
STUDY METHODS
Setting
We will conduct a population-based survey of all persons
diagnosed with TB in Gaborone and Ghanzi, Botswana,
from September 2012 to March 2016. Botswana is a pol-
itically and economically stable country with a strong
national HIV antiretroviral programme and a universal
healthcare system. Half of the population of ∼1.8
million people is concentrated in urban areas. Kopanyo
study staff will recruit participants from two sites: (1) the
capital city, Gaborone (population 231 592) and (2) the
rural town of Ghanzi (population 44 100). These two
sites differ with regard to HIV prevalence (23% in
Gaborone, 16% in Ghanzi). The population of
Gaborone is primarily Tswana, the dominant ethnic
group in Botswana, whereas the population of Ghanzi is
primarily indigenous San (figure 1). Gaborone, the
largest urban centre and its surrounding suburbs,
contain nearly 20% of Botswana’s population. Gaborone
has one of the highest prevalences of HIV infection in
the world,20 and ∼70% of persons with TB in Gaborone
are also infected with HIV.11 Ghanzi is in rural Western
Botswana, where the vast majority of the population lives
on large farms and often in crowded houses. There is
little or no migration within the area. Over the past two
decades, the TB notification rate (defined as the
number of new and relapse TB cases notified per year)
in Ghanzi has consistently been the highest in the
country and one of the highest in the world, at 722 per
100 000 population per year.11 20
Sample size calculation and sample selection
To decrease the potential bias introduced by an analysis
of only a sample of the population, we aim to enrol the
entire population of patients with TB disease diagnosed
during a 4-year period. Thus, sample size calculation or
selection was not applicable to our design.
Participant recruitment
Management of TB is fully integrated into the primary
healthcare system, and services are provided through dis-
trict hospitals, clinics and health posts. Trained health-
care workers and lay community volunteers provide
medical care, social support and directly observed
therapy (DOT) for patients with TB. Participants will be
recruited from TB clinics, DOT centres and HIV care
clinics (details regarding inclusion and exclusion criteria
are provided in online supplementary information S1).
Participants will be identified and enrolled at the time
of their TB diagnosis or during the initiation of TB treat-
ment (figures 2 and 3). Close contacts of TB index
cases identified through routine programmatic contact
investigation activities will be prospectively enrolled and
linked to the index case. This will allow for easy estab-
lishment of epidemiological links should they be diag-
nosed with TB in the future and consequently become
study participants.
Determination of coverage completeness
Understanding completeness of case ascertainment in
this study is crucial for valid interpretation and general-
isation of the results.16 To do this, we will:
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Figure 1 Districts and cities selected for this tuberculosis transmission study.
Figure 2 Overview of the study procedures and data collection. GPS, Global Positioning System; TB, tuberculosis.
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A. Access the electronic records and database of the
Botswana National TB Program to determine the
number of patients diagnosed and treated in each
city (TB reporting is mandatory in Botswana).
B. Use the official Botswana National TB Treatment
Register to identify patients who are enrolled for
treatment, including persons with sputum smear-
negative disease. This will be performed through
periodic on-site visits to all clinics.
C. Use clinic logs of samples submitted for microscopy
or cultures (direct verification through on-site clinic
visits), register logs of samples received and periph-
eral laboratories (through full-time staff based at
those facilities) and through periodic assessment of
the central data register at the National TB
Reference Laboratory.
Data collection
At the time of enrolment, a sputum sample will be
obtained from all participants (detailed information
regarding data elements is provided in online supple-
mentary information S2). The sputum will be cultured
and, if positive, the isolate will be genotyped using
24-locus mycobacterial interspersed repetitive
units-variable number of tandem repeats (MIRU-VNTR,
see online supplementary information S3 for
details).21 22 All cultured isolates will also be tested for
susceptibility to first-line antituberculosis drugs. Isolates
found to be resistant to rifampin or isoniazid will be
tested for susceptibility to second-line drugs.
Additionally, each participant will be interviewed with a
standardised questionnaire to obtain demographic,
social, behavioural and clinical information. If needed,
additional or confirmatory clinical information will be
collected from paper and electronic medical records,
and TB registers. HIV testing results will be collected for
all enrolled participants. If a patient does not have a
documented HIV test result in the 3 months prior to
enrolment, HIV testing will be performed according to
Botswana HIV/AIDS policy guidelines.11
For all participants, the locations of residences (plot
numbers), work place, healthcare facilities visited and
places of social gathering, such as churches and bars,
will be collected and translated into global positioning
system coordinates.23 Approximate dates and frequency
for visiting each social venue will also be recorded. If
home plot numbers are not available, addresses will be
physically located by the study staff and Global
Positioning System (GPS) coordinates will be collected
using handheld devices (refer to online supplementary
information S4 for details regarding geocoding
procedures).
Assessing TB transmission
For more than two decades, molecular characterisation
of Mtb, or TB genotyping, when combined with epi-
demiological data, has been used as a proxy for TB
transmission. The proportion of cases that belong to a
genotype cluster is influenced by the discriminatory
power of the genotyping approached used. Currently,
the most commonly used genotyping approaches
include insertion sequence 6110 (IS6110) restriction
fragment length polymorphism (RFLP), spoligotyping
and MIRU-VNTR.14 Relative to IS6110-RFLP,
MIRU-VNTR typing does not have to exclude isolates
with a low IS6110 copy number, has a faster turnaround
time and it is high throughput. Both MIRU-VNTR and
spoligotyping allow for easier interlaboratory compari-
sons.24 However, MIRU-VNTR has significantly higher
discriminatory power than spoligotyping and equal to
that of the IS6110-RFLP.14 Although less discriminatory
than whole genome sequencing,25 the advantage of
24-loci MIRU-VNTR has increased its use for TB molecu-
lar epidemiological studies and it is currently considered
the gold standard for large population-based TB trans-
mission studies.18
In this study, genotype clusters will be defined as two
or more TB cases with Mtb isolates with the same
24-locus MIRU-VNTR results. Non-clustered TB cases
will have isolates that have non-matching, or unique,
Figure 3 Simplified algorithm for participant identification, enrolment and study procedures. TB, tuberculosis.
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24-locus MIRU-VNTR results. Among genotype clustered
cases, patient interview, symptom onset and treatment
dates, and geospatial data will be used to further categor-
ise putative transmission events into one or more of the
following types14 23 26 27:
A. Household transmission—two or more patients with
matching genotypes residing in the same house.
B. Workplace transmission—two or more patients with
matching genotypes working in the same venue.
C. School transmission—two or more patients with
matching genotypes that reported congregating in
the same school, college, university or other educa-
tional venue.
D. Social setting transmission—two or more patients
with matching genotypes that reported congregating
in the same social setting (bar, church, etc).
E. Healthcare facility transmission—two or more
patients with matching genotypes who reported visit-
ing a healthcare facility (clinic or hospital) at the
same time.
F. Residence/neighbourhood transmission—two or
more patients with matching genotypes residing in
close geographic proximity (eg, spatial scanning
methodology or by politically defined areas, such as
neighbourhoods or districts).
G. Social network transmission—two or more patients
with matching genotypes linked by naming each
other as someone they spent time with when they
were potentially infectious or when the person they
spent time with was potentially infectious.
H. Suspected transmission of unknown origin—two or
more patients with matching genotypes who are not
members of any of the above defined cluster types.
It is possible that multiple transmission event types
can occur for an individual participant. This study aims
to quantify the amount of TB attributed to each of the
aforementioned transmission event types to guide public
health action to interrupt ongoing TB transmission in
the community. These categories will not be considered
mutually exclusive. The putative infectious period for
index cases will be 12 months prior to their TB diagno-
sis. For select clusters, we will conduct intensive field or
cluster investigations to further identify the people
exposed to participants during their infectious periods.
The resultant lists of persons known to have been
exposed will then be prioritised for TB screening and
evaluation. These intensive field investigations are
intended to lead to early identification of people with
undiagnosed TB disease or provision of TB preventive
therapy for people exposed and infected. We acknow-
ledge the potential bias that can be introduced by exclu-
sion of prisoners from our study. Exclusion of prisoners
might preclude the identification of TB cases resulting
from community-based transmission events who were
later imprisoned for the remaining duration of the
study. However, given that our study extends for a 4-year
period, it allows enrolment of most TB cases imprisoned
for shorter periods. Further, our procedures include
extensive data collection regarding prior time and place
of imprisonment, potentially allowing the identification
of TB transmission events occurring in those settings.
Cluster investigations
In collaboration with the Government of Botswana, we
will select several TB genotype clusters based on public
health importance (eg, MDR-TB transmission,
healthcare-associated transmission, multijurisdictional
transmission or suspected transmission of unknown
origin) to intensively investigate. Study participants
within selected clusters will be reinterviewed. The rein-
terviews will focus on social history, behaviours (such as
excessive alcohol use, illicit drug use, tobacco smoking,
exposure to persons known to have TB, sexual partners),
identification of places where they work and spend their
leisure time, which healthcare facilities they have visited,
foreign travel and incarceration history. Responses
during these interviews will be used as prompts for sub-
sequent interviews among other participants in the
cluster. Venues and neighbourhoods with high propor-
tions of epidemiologically or genotypically linked cases
of TB can be prioritised for intensified case-finding
activities.
Geospatial clustering
Spatial scan statistics can be used to identify locations
with a high concentration of disease, including
TB.23 27 28 SaTScan V.9.1.0 will be employed to identify
geographic areas with a larger-than-expected rate of dis-
crete TB genotype clusters using all other culture-
positive cases of TB counted during the study as the
background rate.23 29 In brief, all enrolled participants
with TB disease and genotype results will be aggregated
by genotype according to residential address. Thus, each
genotype will be the unit of analysis and scanned separ-
ately. Then, applying a purely spatial perspective, the
number of TB transmission events in an area, assuming
a Poisson distribution, will be estimated by SaTScan gen-
erated circular zones of various sizes up to a maximum
radius of 1 km. A log-likelihood ratio will be calculated
for each zone in comparison with all possible zones,
with the maximum likelihood ratio representing the
zone most likely to identify spatial clustering for each
genotype. A Monte Carlo simulation with 999 repetitions
will be used to determine the distribution of the scan
statistic under the null hypothesis of spatial randomness;
significant spatial clusters will be chosen with an α of
p<0.05. No duplicative case counting will occur.
ANALYTIC PLAN AND REPORTING OF RESULTS
First, we will determine whether each patient belongs to
a genotype-defined cluster or not. Since we expect that
case detection will be high, we will assume that non-
clustered patients had either imported their infection
from an area outside the study, or that the infection that
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led to disease did not happen recently. The primary ana-
lyses to be performed are:
1. Describe the diversity of Mtb genotypes and lineages
in Botswana, and after stratification by geographic
region (Ghanzi vs Gaborone) and/or HIV status.
2. Determine the proportion of TB cases by genotype
cluster types (ie, healthcare facility-based cluster,
household cluster, etc).
3. Identify geographic areas with high concentrations of
TB disease and/or larger-than-expected rates of
clustering.
4. Using cases with unique genotypes as a referent
population, determine demographic, behavioural
and clinical risk factors associated with clustering.
The results of this study will provide information
required to identify currently unknown social networks,
locations and geographic areas of recent and perhaps
ongoing TB transmission as well as the identification of
TB outbreaks in communities with varying prevalence of
HIV infection. We will use this information to identify
neighbourhoods, healthcare facilities and social net-
works associated with increased levels of transmission
that could benefit from targeted interventions. We will
strictly adhere to recently published standards for
reporting of molecular epidemiology for infectious
diseases.15 18
ETHICS AND HUMAN SUBJECT PROTECTION
Written informed consent will be obtained from all par-
ticipants aged ≥18 years or their parents or legal guar-
dians if <18 years. Assent for participation will be
obtained from all minors able to provide it prior to
obtaining consent from their legal guardians. Consent
and assent for participation in the study will be obtained
in the participant’s native language.
Anticipated benefits to participants
Benefits to the participant will include a very compre-
hensive assessment of his/her health needs and/or pro-
blems interacting with the healthcare system. The
antituberculosis drug susceptibility results of all Mtb iso-
lates will be made available to the treating clinician to
inform the clinical management of disease for any
patient diagnosed, as part of this study. Current national
guidelines indicate first-line drug susceptibility testing to
be performed on all culture-positive samples. Mtb
culture is routinely indicated only for children
(<12 years of age) and for patients considered at risk for
MDR TB. All clinical management decisions will be
deferred to the treating physician.
Risks and methods to minimise risks
The most important social and psychological risk will be
having a breach in confidentiality and/or one’s TB or
HIV status inadvertently disclosed. Every effort will be
made to ensure the confidentiality of the participants
enrolled in this study. At the time of the interview, the
participant’s name and contact information will be
linked with an identification number. Thereafter, the
participant will only be identified by this number. No
personal names and no contact information will be
recorded in study data forms nor in the study database.
Monitoring of adverse incidents
At the close of each interview (including interviews for
in-depth cluster investigation), we will assess the occur-
rence of any adverse events that were the result of par-
ticipating in the Kopanyo study. We will record and
report all adverse incidents in accordance with the
Institutional Review Boards (IRBs) that approved the
study.
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